Tag:
Amylin
Latest Headlines
Latest Headlines
Big-name pharmas peer at Amylin's books to prep for bids
The world's biggest drugmakers have lined up to take a look at Amylin's books as the U.S.-based company prepares to entertain a first round of bids.
Icahn seeks records on why Amylin said no to Bristol-Myers
The spat between billionaire investor Carl Icahn and Amylin Pharmaceuticals was turned up a notch as Icahn filed suit to find out why the company rejected an offer from Bristol-Myers Squibb.
AstraZeneca investors lobby for management shake-up
The knives are out at AstraZeneca, as investors are agitating for big changes at the troubled drugmaker.
Amylin's OH plant prepped for Bydureon's U.S. debut
In anticipation of the U.S. approval of Bydureon, San Diego's Amylin Pharmaceuticals ( $AMLN ) was already amping up production of the diabetes drug at its West Chester Township, OH, plant where...
Amylin gets FDA OK for weekly diabetes drug Bydureon
Say hello to Bydureon , a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ( $AMLN ) developed the drug using controlled release drug
Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup
Alkermes ( $ALKS ) has come through the divorce between its partners Amylin ( $AMLN ) and Eli Lilly ( $LLY ) unscathed, with all of its royalty rights to sales of extended-release exenatide or Bydureon ,...
Amylin gets Byetta custody in split with Lilly
It's splitsville for Eli Lilly and Amylin Pharmaceuticals. The diabetes-drug partners have decided to go their separate ways, with Amylin ( $AMLN ) paying Lilly $250 million for the rights to exanatide
Europe's Bydureon approval is victory for Alkermes
Tuesday's European approval of Bydureon, Amylin Pharmaceuticals' once-weekly injectable type 2 diabetes medication, can be considered a victory for Waltham, MA-based Alkermes' drug-delivery
FDA rejects diabetes drug that includes Alkermes' delivery tech
The FDA's rejection Tuesday of the diabetes drug Bydureon is being reported as a big loss for all three companies with a stake in the once-a-week therapeutic driven by Alkermes' drug delivery
FDA posts observations from Amylin plant visit
Disregard of contamination control procedures and improper inspection of raw materials are two of 10 observations made by FDA inspectors during a late 2009 inspection of the plant where Amylin makes
